Giuffra M E, Sethy V H, Davis T L, Mouradian M M, Chase T N
Experimental Therapeutics Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland 20892.
Mov Disord. 1993;8(1):47-50. doi: 10.1002/mds.870080109.
The clinical effects of central glutamatergic stimulation by the glycine prodrug milacemide were studied in six patients with Parkinson's disease under double-blind, placebo-controlled conditions. When administered as monotherapy at a single oral dose of 1,200 mg, the drug increased overall parkinsonian severity transiently, mostly due to an effect on rigidity. Milacemide did not, however, alter levodopa-induced dyskinesias. These results support the view that drugs acting on the glutamatergic system can influence motor function in patients with extrapyramidal movement disorders and that pharmaceutical agents that selectively block certain subtypes of glutamate receptors may ameliorate parkinsonian symptoms.
在双盲、安慰剂对照条件下，对6例帕金森病患者研究了甘氨酸前体药物米拉醋胺对中枢谷氨酸能的刺激作用的临床效果。当以1200毫克单剂量口服作为单一疗法给药时，该药物会短暂增加帕金森病的整体严重程度，主要是由于对僵硬的影响。然而，米拉醋胺并未改变左旋多巴引起的运动障碍。这些结果支持以下观点，即作用于谷氨酸能系统的药物可影响锥体外系运动障碍患者的运动功能，并且选择性阻断某些谷氨酸受体亚型的药物可能改善帕金森病症状。
